Skip to content
Search

Latest Stories

Wholesaler surcharges unfair, say independents

Nearly two thirds of independent community pharmacy contractors say their mainline wholesalers have an unfair system of pricing for surcharges, a new survey has revealed.

The National Pharmacy Association (NPA) ran a month-long research in November after seeing continuing complaints from its independent community pharmacy members about aspects of medicines supply.


The results of the 'snapshot' survey released on Friday (Dec 4) showed that nearly seven in 10 respondents felt their mainline wholesalers apply surcharges that are not clearly justifiable and proportionate.

Only one in 10 believed that quotas are allocated equitably, either sometimes or always, while most reported that the number of products on quota has increased over the last six months.

Some respondents stated that they felt national pharmacy chains do not have the same problems as independent pharmacies and are given preferential treatment when it comes to obtaining stock.

In a press release, the NPA said: "A total of 78 per cent respondents said that they have issues with Alliance Healthcare surcharges, more than twice the number for AAH and Phoenix combined. This in part reflects the respective market positions of these three wholesalers."

Neil Bhayani, NPA public affairs manager, commented: “The size of the survey is small, but clear themes did appear, which we want to explore further with pharmaceutical wholesalers. The majority of the complaints we get are about surcharges. We will be asking wholesalers to listen to their independent customers and to review their policies on surcharges.”

This is the third Wholesaler Service Standards survey run by the NPA. The survey in 2018/2019 asked members to score their wholesalers according to a set of markers, including markers for efficiency, customer service and fairness.

Responding to the result of the survey, an Alliance Healthcare spokesperson said: "As a leading pharmaceutical wholesaler, we operate a nationwide, twice-daily delivery service. To help enable us to do this we apply a low spend surcharge as per our terms and conditions.

"We work hard to ensure customers do not incur a surcharge and have a dedicated team in place that can help customers meet their qualifying spend threshold. Details of all surcharges are also available on our website, with helpful information for customers to avoid a surcharge.

"Alliance Healthcare works closely with manufacturers to ensure maximum supply of product to UK patients. In times where demand exceeds supply we may have to apply quotas to give an opportunity to all pharmacies to access stock."

The latest NPA survey, a smaller, snapshot survey which had 118 independent pharmacies participating, was aimed at finding out more about supply issues in the context of Covid-19.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less